These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 12082194

  • 1. Platelet glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: IIb or Not IIb, what is the question?
    Young JJ, Kereiakes DJ.
    J Invasive Cardiol; 2002 Jul; 14(7):404-10. PubMed ID: 12082194
    [Abstract] [Full Text] [Related]

  • 2. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
    Proimos G.
    J Thromb Thrombolysis; 2001 Apr; 11(2):99-110. PubMed ID: 11406724
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis.
    Glaser R, Glick HA, Herrmann HC, Kimmel SE.
    J Am Coll Cardiol; 2006 Feb 07; 47(3):529-37. PubMed ID: 16458131
    [Abstract] [Full Text] [Related]

  • 5. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.
    Zeymer U, Margenet A, Haude M, Bode C, Lablanche JM, Heuer H, Schröder R, Kropff S, Bourkaib R, Banik N, Zahn R, Teiger E.
    J Am Coll Cardiol; 2010 Aug 03; 56(6):463-9. PubMed ID: 20670755
    [Abstract] [Full Text] [Related]

  • 6. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
    Boersma E, Akkerhuis KM, Théroux P, Califf RM, Topol EJ, Simoons ML.
    Circulation; 1999 Nov 16; 100(20):2045-8. PubMed ID: 10562258
    [Abstract] [Full Text] [Related]

  • 7. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH, Ohman EM, Zidar JP, Gretler D, DiBattiste PM, Tcheng JE, Califf RM, Harrington RA.
    Circulation; 2002 Sep 17; 106(12):1470-6. PubMed ID: 12234950
    [Abstract] [Full Text] [Related]

  • 8. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Bhatt DL, Topol EJ.
    JAMA; 2000 Sep 27; 284(12):1549-58. PubMed ID: 11000650
    [Abstract] [Full Text] [Related]

  • 9. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
    Auer J, Berent R, Lassnig E, Weber T, Maurer E, Eber B.
    Herz; 2003 Aug 27; 28(5):393-403. PubMed ID: 12928738
    [Abstract] [Full Text] [Related]

  • 10. Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention.
    Kimmelstiel C, Phang R, Rehman A, Rand W, Miele R, Rhofiry J, MacIsaac DA, Gouveia W, Denier D, Becker RC.
    J Thromb Thrombolysis; 2001 May 27; 11(3):203-9. PubMed ID: 11577258
    [Abstract] [Full Text] [Related]

  • 11. Platelet receptor glycoprotein IIb/IIIa inhibition with eptifibatide in a patient with thrombocytopenia after treatment with abciximab.
    Coto H.
    J Invasive Cardiol; 2000 Oct 27; 12(10):528-31. PubMed ID: 11022214
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention.
    Labinaz M, Ho C, Banerjee S, Martin J, Chen S, Mensinkai S.
    Can J Cardiol; 2007 Oct 27; 23(12):963-70. PubMed ID: 17932572
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of glycoprotein IIb/IIIa-receptor inhibitors during percutaneous coronary intervention.
    Cheng JW.
    Am J Health Syst Pharm; 2002 Nov 01; 59(21 Suppl 7):S5-14. PubMed ID: 12434710
    [Abstract] [Full Text] [Related]

  • 15. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention.
    Kereiakes DJ, Broderick TM, Roth EM, Whang D, Shimshak T, Runyon JP, Hattemer C, Schneider J, Lacock P, Mueller M, Abbottsmith CW.
    Am J Cardiol; 1999 Aug 15; 84(4):391-5. PubMed ID: 10468074
    [Abstract] [Full Text] [Related]

  • 16. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
    Hobbach HP, Schuster P.
    Z Kardiol; 2003 Mar 15; 92(3):213-8. PubMed ID: 12658467
    [Abstract] [Full Text] [Related]

  • 17. IIb's are not IIb's.
    Kereiakes DJ, Runyon JP, Broderick TM, Shimshak TM.
    Am J Cardiol; 2000 Apr 27; 85(8A):23C-31C. PubMed ID: 10793177
    [Abstract] [Full Text] [Related]

  • 18. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Holmes LE, Gupta R, Rajendran S, Luu J, French JK, Juergens CP.
    Cardiovasc Ther; 2016 Oct 27; 34(5):330-6. PubMed ID: 27327862
    [Abstract] [Full Text] [Related]

  • 19. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions.
    Karvouni E, Katritsis DG, Ioannidis JP.
    J Am Coll Cardiol; 2003 Jan 01; 41(1):26-32. PubMed ID: 12570940
    [Abstract] [Full Text] [Related]

  • 20. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial.
    PRICE Investigators.
    Am Heart J; 2001 Mar 01; 141(3):402-9. PubMed ID: 11231437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.